Article
The Health and Human Services Notice of Benefit and Payment Parameters proposed rule for 2024 does not revise policies related to copay assistance and patient deductibles.
All News
Article
A meta-analysis of trials using biologics [adalimumab (ADA), ustekinumab (UST) and secukinumab (SEC)] in the the management of hidradenitis suppurativa (HS) suggests promising results, but more controlled, rigorous studies are needed.
Article
JAK inhibitors are approved for several immune-mediated inflammatory diseases and carry a higher than usual risk of herpes zoster in certain conditions like rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and ulcerative colitis.
Dr. John Cush
Tweet
Is JAKi therapy safe in RA-ILD pts? Italian retrospective study (2018-June 2022) w/ 43 RA pts & HRCT proven ILD (med age 69yrs) & Rx w/ JAKi. After 19 mos F/U, the FVC was stable in 79%, improved in 11%, & worse in 11%. DLCO & HRCT trend was similar. https://t.co/bAqa5wKIYE https://t.co/LnlcQtQnm8
Dr. John Cush
Tweet
The EMAs CHMP has recommended granting a marketing authorisation for Sotyktu (deucravacitinib) for the treatment of moderate to severe plaque psoriasis in adults. https://t.co/WztKcNDFl1 https://t.co/Cq3Cyr3YqX
Dr. John Cush
Tweet
Rretroperitoneal fibrosis Tx is fraut-steroids, tamoxifen, MMF, B cell therapy? OL trial in 8 RPF pts used steroids & mTOR inhibitor sirolimus (2mg/d x 3d; 1mg/d); 12 & 48wks - decr in fibrous tissue 50%, ESR 70%, IgG4 50% w/ normalized renal funct.
https://t.co/9BJchCctDi
Dr. John Cush
Tweet
RANKL-responsive epigenetic mechanism reprograms macrophages into bone-resorbing osteoclasts - study shows that NFATC1 associated superenhancer RNA, which is formed during osteoblast differentiation, can be used as a treatment target to reduce erosions https://t.co/gCITdJKPRP https://t.co/HENbYJcOId
Dr. John Cush
Tweet
Studies in 76 systemic sclerosis (SSc) pts (& animal models of SSc) show fibroblast A20 (enzyme) is downregulated and promotes fibrosis in SSc; but is repressed by DREAM, an A20 negative transcriptional regulator. https://t.co/30PuO4XRuq https://t.co/VJuAJHGbut
Dr. John Cush
Tweet
Join us at RheumNow Live this March!
Dr. Janet Pope ( @janetbirdnope) will be back to discuss decisive therapeutics in RA.
https://t.co/0IkJsGpH6s https://t.co/TwM6AAW97X
Dr. John Cush
Tweet
US population mortality rates compared dermatomyositis (DM) vs polymyositis (PM) in 1981 (12,249) & 2020 (23,608). Downward trend in DM/PM mortality (<7%); plus PM/DM was 2X more likely to be one of mult causes, instead of, sole cause of death. https://t.co/9KZKr8JxUE https://t.co/7acK0eHVku
Dr. John Cush
Tweet
Systematic review of MRI confirm degenerative meniscus tears compared arthroscopic meniscectomy (APM) vs non-surgical or sham Rx. Results: 10 trials, 605 patients showed at 24 mos F/U, no advantage in Function or QOL favoring APM - rec conservative Rx
https://t.co/4CwicQ9Jac https://t.co/3IrSRkNgqp
Dr. John Cush
Tweet
How do you treat latent TB? This and more on last week's RheumNow podcast.
https://t.co/4gUXFUDTFM https://t.co/TgT6ZyewZJ
Dr. John Cush
Tweet
Can something as simple as a cup of coffee with milk have an anti-inflammatory effect in humans?
Apparently so, according to a new study. A combination of proteins and antioxidants doubles the anti-inflammatory properties.
https://t.co/As8lhxnifp https://t.co/eZKD8Y6oTx
Dr. John Cush
Tweet
Amgen launched its adalimumab biosimilar - Amjevita ( FDA approved in 2016), has 2 different discounts— 55% or 5% below Humira's (list $6,922/mo). Another report says Amjevita 40mg given q 2wk will cost $40,497 - $85,494 annually https://t.co/iGtJUa991N https://t.co/PTPTUskUaa
Dr. John Cush
Tweet
1st there was combined Rheum-Derm or Rheum-Pulm clinics. Medscape reports new Rheum-Cardiology clinics at Cleveland Clinic, NYU, Brigham, Stanford. Useful in research, managing Rheum pts a) at hi CV risk, B) having procedures/surgery, c) risk reduction https://t.co/9AqujArSMT https://t.co/3ZVORt9gK9
Dr. John Cush
Tweet
FDA has approved the 1st BTK (Bruton’s tyrosine kinase) inhibitor (Jaypirca™ or pirtobrutinib) for adults with refractory mantle cell lymphoma. BTK inhibitors are also being developed for use in MS, RA, SLE, pemphigus & more https://t.co/gDHbcDpNnT https://t.co/oL0nldQ1fN
Dr. John Cush
Tweet
Last day for early bird pricing!
https://t.co/KwQnDC4Pdz
RheumNow Live is a 1.5-day long meeting that offers pre-learning modules, shorter, concise lectures with clinical context and audience input, more discussion time, and sessions that are relaxed and comprehensive. https://t.co/W4mqIyhgRS
Dr. John Cush
Tweet
Have you listened to last week's RheumNow podcast?
Dr. Cush answers the question--is there such a thing as dry synovitis?
https://t.co/Um0JhCfRDv https://t.co/rXOGWOEnlr
Dr. John Cush
Tweet
Pathogenic Impact of microRNA Cotargeting in Lupus
A group of researchers from the Graduate School of Medicine at Nagoya University in Japan have discovered the impact of microRNA (miRNA) on inflammation in lupus in mice.
https://t.co/j0TRgIaam6 https://t.co/HNJbsTfT7c
Dr. John Cush
Tweet
Study of 58 pediatric patients with Kikuchi-Fujimoto disease saw 15 (26%) with Macrophage Activation Syndr. KFD-MAS+ pts had signif. more skin rash (27%), Steroid Rx(80%), Dz recurrence (33%), lower cell counts (WBC, plt, lymphs) & higher LDH. https://t.co/GINlAJlEHi https://t.co/idhuaAo9T6
